Oncology

Latest News

Value-based care. | Image Credit: irissca - stock.adobe.com

Legal Navigation Services Key to Addressing Disparities in Cancer Care

By Cameron Santoro

July 31st 2025

A significant number of patients with cancer, caregivers, and health care professionals face significant disparities in legal issues, with the most common needs revolving around health insurance, finances, employment, and disability insurance.

Radiotherapy can work synergistically with immunotherapy by reprogramming the tumor microenvironment. | Image credit: Crystallight-stock.adobe.com

Brain Radiotherapy Plus ICIs Boost Survival in SCLC With Brain Metastases

By Jared Kaltwasser

July 30th 2025

As SCLC continues to pose a therapeutic challenge due to rapid progression and early metastasis, the convergence of immunotherapy and precision radiation holds promise to extend survival and improve outcomes. | Image credit: mi_viri - stock.adobe.com

Chemoimmunotherapy Shows Promise for Limited-Stage SCLC in Real-World Study

By AJMC Contributor

July 29th 2025

The findings suggest that inhibition of midkine might be a meaningful tool to improve treatment outcomes in SCLC. | Image credit: Pixel-Shot - stock.adobe.com

Midkine May Play Key Role in SCLC

By Jared Kaltwasser

July 24th 2025

The FDA has issued a complete response letter for RP1 plus nivolumab for advanced melanoma after a PD-1 inhibitor–containing regimen. | Image credit: ra2studio - stock.adobe.com

RP1 Plus Nivolumab Receives CRL for Advanced Melanoma

July 24th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

August 1st 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

August 1st 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

October 23rd 2013

Utilization of Lymph Node Dissection, Race/Ethnicity, and Breast Cancer Outcomes

Zhannat Z. Nurgalieva, MD, PhD Luisa Franzini, PhD Robert O. Morgan, PhD Sally W. Vernon, PhD Xianglin L. Du, MD, PhD

The disparities in survival among node-positive breast cancer patients of African American and Hispanic heritage are not explained by nodal surgery utilization.

October 23rd 2013

Melanoma: From Impossible to Treat to Poster Child for Targeted Therapies

An AJMC Panel Discussion

October 23rd 2013

Challenges in Oncology Practice

October 23rd 2013

Status in the States: In Louisiana, Will Privatization Affect Efforts to Stop Cancer?

Mary K. Caffrey

October 23rd 2013

Cancer Treatment: Cost vs. Value

For many, a bill for more than a quarter million dollars is nothing to scoff at-but while treating those with cancer, these costs are all too common.

October 23rd 2013

Positive Idelalisib Data End Late-Stage CLL Trial

October 22nd 2013

First Generic Version of Capecitabine Gains FDA Approval

October 22nd 2013

Volasertib Given Breakthrough Therapy Designation

October 22nd 2013

In Historic Vote, FDA Backs Perjeta for Pre-surgical Breast Cancer Treatment

October 22nd 2013

If $100G Cancer Drugs Worry You, Join Us! 'Cancer Drug Racket' Article, 'Morning Joe' Segment Draw Attention to Debate Over Balancing Care, Cost in Oncology

With the US Food and Drug Administration busier than ever with breakthrough and priority review designations, and the rise of genetic-based treatments offering new hope for patients and families, the pressure is on oncologists to push the limits in care. But if it costs $200,000 to extend life just a few weeks, does that make sense? Are doctors having that conversation? When they do, are patients hearing it? These are the very issues that will be on the table in Baltimore Nov. 14-15 when The American Journal of Managed Care convenes experts from the front line.

October 4th 2013

Providers and Patients Feel Government Shutdown Strain

As the government shutdown drags on, patients and providers are feeling the strain.

October 4th 2013

ACA Provisions Impacting Cancer Care, the Focus of CHAMPS Oncology's Latest Brief

From the Physician Quality Reporting System's aim to boost quality measures reporting to the potential for accountable care organizations to transform care delivery, this brief sheds light on these and other key ACA provisions impacting cancer care.

Bruce Feinberg Discusses Differences in Managing Oncology in Medicaid and Commercial Populations

October 3rd 2013

Bruce Feinberg Discusses Differences in Managing Oncology in Medicaid and Commercial Populations

Bruce Feinberg, DO, vice president and chief medical officer, Cardinal Health Specialty Solutions, says that the populations of Medicaid and commercial patients have historically been different.

Segment 5 - Future Directions

September 18th 2013

Segment 5 - Future Directions

In the final segment of the panel discussion, each panel member gave their final thoughts on the discussion topic.

Segment 4 - Errors in Genetic Testing

September 18th 2013

Segment 4 - Errors in Genetic Testing

In this segment, Dr Berger asked about errors in test result interpretation, as well as the problem of inconsistent testing. Panelists showed concern with unregulated direct-to-consumer testing.

Segment 3 - The Provider's Role and Costs Associated With Genetic Testing

September 18th 2013

Segment 3 - The Provider's Role and Costs Associated With Genetic Testing

It is up to physicians to seek education and training on genetics. Panelists agree that it is important for patients to speak with a genetic counselor even if it is over the phone.

Segment 2 - Impact of the SCOTUS Decision on Genetic Testing

September 18th 2013

Segment 2 - Impact of the SCOTUS Decision on Genetic Testing

Dr Berger asked the panel how both the June 2013 Supreme Court decision and the Angelina Jolie disclosure impacted genetic testing and counseling. After the Supreme Court's decision there was an influx of inexpensive and more comprehensive genetic tests available.

Segment 1 - Genetic Testing Today

September 18th 2013

Segment 1 - Genetic Testing Today

After introducing panelists, Otis Brawley, MD, chief medical officer, American Cancer Society, David H. Finley, MD, FACS, national medical officer, Enterprise Affordability and Policy, Cigna Healthcare, Joy Larsen-Haidle, MS, genetic counselor, Hubert H. Humphrey Cancer Center, Ellen T. Matloff, MS, research scientist, Department of Genetics, director, Cancer Genetic Counseling, Yale Cancer Center and Rebecca Nagy, president, National Society of Genetic Counselors, moderator, Jan Berger MD, MJ, president & CEO, Health Intelligence Partners, editor-in-chief, The American Journal of Pharmacy Benefits, asked the panel to identify the current unmet needs and challenges in genetic testing.

September 18th 2013

AJMC: In Treating Prostate Cancer, Choices for Patients and Challenges for Clinicians, Payers

Not long ago, the range of options for a man diagnosed with prostate cancer was fairly narrow: surgery, radiation, or limited chemotherapy choices. Today, there are so many new therapies on the market, with so many possibilities for drug combinations and sequencing, that the questions for clinicians are complex: It's not just which therapy or which drug, but for how long and when do you switch?

September 17th 2013

Curing the Cancer Crisis

Remedies needed: Better palliative care, patient-centered approach

September 16th 2013

Referring Patients for Telephone Counseling to Promote Colorectal Cancer Screening

Roger Luckmann, MD, MPH Mary E. Costanza, MD Milagros Rosal, PhD Mary Jo White, MS, MPH Caroline Cranos, MPH

In this pilot study, primary care providers refer patients to a telephone counselor who provides education about colorectal cancer screening and performs motivational interviewing as needed to promote screening.

Segment 7 - The Payer's Role and Future Trends

September 12th 2013

Segment 7 - The Payer's Role and Future Trends

Panelists all agree that there needs to be evidence and guidelines for both payers and providers. There are not enough resources to try every drug on every patient. Although it will be costly, there needs to be evidence on putting these drugs together as combinations.

Segment 6 - Personalized Medicine

September 12th 2013

Segment 6 - Personalized Medicine

Dr Crawford said that in order to pick the appropriate treatment for a diagnosed patient with prostate cancer, it is important to think outside of the box. The National Comprehensive Cancer Network (NCCN) and the American Urological Association (AUA) offer castration-resistant prostate cancer (CRPC) guidelines that serve as the best guideline for payers.

Segment 5 - Emerging Agents

September 12th 2013

Segment 5 - Emerging Agents

It is an exciting time for prostate cancer due to the growth in new treatments. Dr George said that it is, in fact, both exciting and daunting to have all of these new agents being developed. Currently, there is a shortage in data for practitioners in using the new agents in sequence or combination.

Segment 4 - Advances and Challenges in Prostate Cancer

September 12th 2013

Segment 4 - Advances and Challenges in Prostate Cancer

In this segment of the panel discussion, Dr Fendrick asks the panelists if there is now a sense of optimism in reducing the mortality and quality gaps in prostate cancer treatment due to targeted screening and new molecular diagnostics, and immunotherapies.

September 12th 2013

Cancer Care Reaches Near Crisis

The ability to treat cancer in a growingly aging population is reaching a near crisis level in the healthcare community.

Segment 3 -Managing Treatment Options and Shared Decision Making

September 12th 2013

Segment 3 -Managing Treatment Options and Shared Decision Making

Dr George notes that in an ideal world a multidisciplinary clinic would not be necessary. Multidisciplinary clinics deliver the tools to practitioner to make the best decisions for their patients.

Segment 2 - Team-Based Approach to Treatment

September 12th 2013

Segment 2 - Team-Based Approach to Treatment

In this segment, panelists examine prostate cancer treatment as a model for team-based approach. Panelists agree that there is a need for a multidisciplinary approach to care. There

September 11th 2013

U.S. Cancer-Care Delivery is 'In Crisis': Report

Cancer treatment has grown so complex, many U.S. doctors can't keep up with new information and are offering incorrect treatment, failing to explain options and leaving patients to coordinate their own care.

September 10th 2013

Cancer Patient Stuck with Higher Bills as Obama Pre-existing Condition Plan Runs Low on Cash

Coping with advanced cancer, Bev Veals was in the hospital for chemo this summer when she got a call that her health plan was shutting down. Then, the substitute insurance she was offered wanted her to pay up to $3,125, on top of premiums.

...

170 171 172 173 174 175 176 177 178

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions